CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment

Rhea-AI Summary

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, announced its participation in a Virtual Investor KOL Connect segment. The event featured key members of the CNS management team, including:

• John Climaco, Chief Executive Officer
• Dr. Sandra Silberman, Chief Medical Officer
• Dr. Don Picker, Chief Scientific Officer

Additionally, Dr. Samuel Goldlust, a leading Neuro-Oncologist and Key Opinion Leader, joined the segment. Dr. Goldlust currently serves as the Medical Director of Neuro-Oncology at Saint Luke's Health System and was previously an investigator in CNS's global potentially pivotal study of Berubicin.

The segment covered a corporate overview, discussed the unmet need in glioblastoma multiforme (GBM), and explored the opportunities for CNS Pharmaceuticals in this field.

Positive

• Participation in Virtual Investor KOL Connect segment, potentially increasing investor awareness
• Involvement of a leading Neuro-Oncologist and Key Opinion Leader in the segment
• Focus on addressing unmet needs in glioblastoma multiforme (GBM), a challenging area in oncology

Negative

• None.

Segment featuring members of the CNS management team and leading Neuro-Oncologist and Key Opinion Leader, Dr. Samuel Goldlust

Access the segment here

HOUSTON, TX / ACCESSWIRE / October 10, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it participated in a Virtual Investor KOL Connect segment. The segment can be accessed here.

As part of the event, John Climaco, Chief Executive Officer, Dr. Sandra Silberman, Chief Medical Officer, Dr. Don Picker, Chief Scientific Officer, and Dr. Samuel Goldlust, a leading Neuro-Oncologist and Key Opinion Leader who currently serves as the Medical Director of Neuro-Oncology at Saint Luke's Health System and previously an investigator in the Company's global potentially pivotal study of Berubicin, provided a corporate overview, discussed the unmet need in glioblastoma multiforme (GBM) and discussed the CNS opportunity.

About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.

For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook, and LinkedIn.

CONTACTS:

Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
CNSP@jtcir.com

SOURCE: CNS Pharmaceuticals, Inc.

View the original press release on accesswire.com

FAQ

What was the purpose of CNS Pharmaceuticals' (CNSP) participation in the Virtual Investor KOL Connect segment?

CNS Pharmaceuticals participated to provide a corporate overview, discuss the unmet need in glioblastoma multiforme (GBM), and explore the company's opportunities in developing novel treatments for brain and central nervous system cancers.

Who were the key participants from CNS Pharmaceuticals (CNSP) in the Virtual Investor KOL Connect segment?

The key participants from CNS Pharmaceuticals were John Climaco (CEO), Dr. Sandra Silberman (CMO), and Dr. Don Picker (CSO). They were joined by Dr. Samuel Goldlust, a leading Neuro-Oncologist and Key Opinion Leader.

What is the significance of Dr. Samuel Goldlust's participation in the CNS Pharmaceuticals (CNSP) Virtual Investor KOL Connect segment?

Dr. Goldlust's participation is significant because he is a leading Neuro-Oncologist, currently serves as the Medical Director of Neuro-Oncology at Saint Luke's Health System, and was previously an investigator in CNS's global potentially pivotal study of Berubicin.

What is the main focus of CNS Pharmaceuticals' (CNSP) research and development?

CNS Pharmaceuticals specializes in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, with a particular focus on addressing the unmet need in glioblastoma multiforme (GBM).